To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD

Prior treatment

• Serious trauma or surgery performed within 4 weeks before the screening date
• Participants who are currently participating in another clinical trial or have participated in another clinical trial within 30 days before the screening date
• Participants with a previous history of using NDTx-01, the investigational device
• Participants who have a change in the usage or dosage of drugs which can significantly affect one's sociality, or a change in participation in treatment/rehabilitation/education programs that can significantly affect one's sociality within 8 weeks before the baseline date of the clinical trial

Other illness

• Severe acute/chronic medical or mental illness
• Participants with other disabilities such as severe neurological diseases (e.g. brain lesions, mental disorders, etc.)

Other

• A risk of clinically significant behavioral problems, emotion regulation problems, psychotic symptoms, self-harm, or other harm at a level that affects the treatment process
• In other cases where the investigator determines that participation in the clinical trial is inappropriate due to ethical reasons or the possibility of influencing the results of the clinical trial

• Children and adolescents between the ages of 10 and 18
• Diagnosed with autism spectrum disorder (ASD) or social communication disorder (SCD) based on the clinical judgment of a psychiatrist according to DSM-5 diagnostic criteria
• Participants who are able to install 'NDTx-01' on an Android smartphone and use it alone or with the help of their guardian
• Participants who are able to comply with the recommended application time for the investigational medical device (6 weeks, 30 times, 5 times a week)
• Participants who have agreed not to use any other medical devices besides the investigational medical device during the clinical trial
• Participants who agree that there should be no change in the use of drugs which can significantly affect one's sociality during the clinical trial (If there is a drug being taken during screening, it can be taken continuously, but the total daily dose, ingredients, etc., should remain unchanged until the end of the study visit.)
• Participants who agree not to participate in other Applied Behavior Analysis (ABA) treatment/rehabilitation/education, social treatment/rehabilitation/education program (If there is treatment/rehabilitation/education being received during screening, it can be received continuously, but the number of applications and treatment methods should remain unchanged until the end of the study visit.)
• Participants who and whose parents (legal guardians) have volunteered to participate in this clinical trial and have given written consent to the subject description and consent form
• Participants willing to comply with the clinical trial procedures